Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Down 52.0% in August

by · The Cerbat Gem

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) saw a significant drop in short interest in August. As of August 31st, there was short interest totaling 173,858 shares, a drop of 52.0% from the August 15th total of 362,103 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 247,213 shares, the days-to-cover ratio is currently 0.7 days.

Zhengye Biotechnology Price Performance

NASDAQ:ZYBT opened at $1.55 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 1.14. Zhengye Biotechnology has a 52 week low of $0.62 and a 52 week high of $11.45. The stock’s 50-day moving average price is $1.62 and its 200-day moving average price is $1.13.

Institutional Trading of Zhengye Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd lifted its position in shares of Zhengye Biotechnology by 71.4% during the 4th quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock valued at $68,000 after buying an additional 24,697 shares in the last quarter. WINTON GROUP Ltd increased its holdings in Zhengye Biotechnology by 193.8% in the 4th quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock worth $73,000 after acquiring an additional 41,750 shares in the last quarter. Millennium Management LLC purchased a new stake in Zhengye Biotechnology in the 3rd quarter worth $38,000. Citadel Advisors LLC acquired a new position in Zhengye Biotechnology during the third quarter worth $31,000. Finally, Jane Street Group LLC acquired a new position in Zhengye Biotechnology during the second quarter worth $1,158,000.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Zhengye Biotechnology from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

View Our Latest Stock Report on ZYBT

About Zhengye Biotechnology

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Featured Stories